Avovida (Avocado Soy Unsaponifiables) Clinical Evidence

Clinical Rheumatology

Pavella K, et al. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. 2010 Jun; 29(6):659-70.

Topic:

How does ASU compare with chondroitin sulfate as a treatment for osteoarthritis?

Background:

Osteoarthritis is the most common form of arthritis and the leading cause of long-term disability in the U.S. The weight of the scientific evidence shows that chondroitin sulfate is effective in treating osteoarthritis. How does ASU compare?

Study Type:

Human clinical intervention trial

Study Design:

Subjects received either ASU or chondroitin for 6 months, with a 2-month follow-up period. Subjects were evaluated using the WOMAC-index, the Lequesne-index, pain during movement, and pain at rest.

Dosage:

300 mg/day for 6 months

Subjects:

361 subjects

Results:

Both groups experienced a 50% decrease in the WOMAC-index.  There was a slight continued improvement during the post-treatment period. There was no statistically significant difference between the groups.

Conclusion:

“Overall efficacy has been rated excellent and good in more than 80% of the patients in both groups. Both drugs were safe and well tolerated. The first direct comparison between avocado soybean unsaponifiable 300 mg once daily and chondroitin sulfate three times daily revealed no difference in efficacy or safety aspects between 1 capsule ASU 300 mg per day and 3 capsules chondroitin sulfate per day.”

 

Ortopedia, Traumatologia, Rehabilitacja

Kucharz EJ. Application of avocado/soybean unsaponifiable mixtures (piascledine) in treatment of patients with osteoarthritis. 2003 Apr 30; 5(2):248-51.

Topic: 

How does ASU affect structures in the joint as well as symptoms of osteoarthritis?

Background: 

Arthritis leads to the degradation of cartilage. Can ASU protect cartilage and reduce the painful symptoms of arthritis?

Study Type: 

Review paper

Study Design: 

Subjects received either ASU or chondroitin for 6 months, with a 2-month follow-up period. Subjects were evaluated using the WOMAC-index, the Lequesne-index, pain during movement, and pain at rest.

Dosage:

300 mg/day for 6 months

Subjects: 

361 subjects

Summary: 

The authors note that well-controlled clinical trials on ASU have shown it effectively alleviates symptoms in patients with osteoarthritis. Specifically, it was found to:

  • Improve functional indices of joint health
  • Result in a decrease in pain
  • Cause a reduction in analgesic drug demand 

Conclusion:

In addition to alleviating symptoms, ASU additionally has a structure-modifying action. “Administration of the drug within two years resulted in delayed destruction of the joints as shown in radiological evaluation. Application of piascledine [ASU] is very well tolerated.”

Mechanism of Action

ASU improves joint function and alleviates joint pain by helping reduce erosion of cartilage. In vitro research indicates several mechanisms of action. It increases the synthesis of collagen and proteoglycan (which helps make up the extracellular matrix of connective tissue). It helps preserve hydroxyproline, which promotes collagen stability. It decreases the synthesis of fibronectin, a protein that is elevated in arthritis patients. And it inhibits the release of substances such as metalloproteinases and proinflammatory cytokines, which play a role in the development of osteoarthritis.